Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1166 ARTÍCULOS , VIENDO DEL 1111 AL 1125

Is early-life iron exposure critical in neurodegeneration?

Hare DJ, Arora M, Jenkins NL, Finkelstein DI, Doble PA, Bush AI.

Nat Rev Neurol. 2015 Sep;11(9):536-44. doi: 10.1038/nrneurol.2015.100. Epub 2015 Jun 23.

Neuroimaging signature of neuropsychiatric disorders

Worbe Y.

Curr Opin Neurol. 2015 Aug;28(4):358-64. doi: 10.1097/WCO.0000000000000220.

Why bother using non-human primate models of cognitive disorders in translational research?

Camus S, Ko WK, Pioli E, Bezard E.

Neurobiol Learn Mem. 2015 Oct;124:123-9. doi: 10.1016/j.nlm.2015.06.012. Epub 2015 Jun 29.

Can clock drawing differentiate Alzheimer's disease from other dementias?

Tan LP, Herrmann N, Mainland BJ, Shulman K.

Int Psychogeriatr. 2015 Oct;27(10):1649-60. doi: 10.1017/S1041610215000939. Epub 2015 Jul 3.

Identifying the components of clinical vignettes describing Alzheimer's disease or other dementias: a scoping review

Randhawa H, Jiwa A, Oremus M.

BMC Med Inform Decis Mak. 2015 Jul 15;15:54. doi: 10.1186/s12911-015-0179-x.

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, Thompson PM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):865-84. doi: 10.1016/j.jalz.2015.04.005.

Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders

Cai Y, An SS, Kim S.

Clin Interv Aging. 2015 Jul 14;10:1163-72. doi: 10.2147/CIA.S85808. eCollection 2015.

Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease

Cummings J, Zhong K.

Clin Pharmacol Ther. 2015 Nov;98(5):483-5. doi: 10.1002/cpt.190. Epub 2015 Aug 31.

Beta Amyloid Hallmarks: From Intrinsically Disordered Proteins to Alzheimer's Disease

Korsak M, Kozyreva T.

Adv Exp Med Biol. 2015;870:401-21. doi: 10.1007/978-3-319-20164-1_14.

The Concept of Subconsciousness in Alzheimer's and Parkinson's Diseases

Agid Y.

J Parkinsons Dis. 2015;5(3):643-5. doi: 10.3233/JPD-150573.

The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact

Haeffner-Cavaillon N, Devos P, Ledoux S, Ménard J.

Alzheimers Res Ther. 2015 Sep 26;7(1):60. doi: 10.1186/s13195-015-0144-z.

Changes in Nutritional Status after Deep Brain Stimulation of the Nucleus Basalis of Meynert in Alzheimer's Disease--Results of a Phase I Study

Noreik M, Kuhn J, Hardenacke K, Lenartz D, Bauer A, Bührle CP, Häussermann P, Hellmich M, Klosterkötter J, Wiltfang J, Maarouf M, Freund HJ, Visser-Vandewalle V, Sturm V, Schulz RJ.

J Nutr Health Aging. 2015 Oct;19(8):812-8. doi: 10.1007/s12603-015-0595-8.

Semantic profiles in mild cognitive impairment associated with Alzheimer's and Parkinson's diseases

Guidi M, Paciaroni L, Paolini S, Scarpino O, Burn DJ.

Funct Neurol. 2015 Apr-Jun;30(2):113-8. doi: 10.11138/fneur/2015.30.2.113.

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease

Gui Y, Liu H, Zhang L, Lv W, Hu X.

Oncotarget. 2015 Nov 10;6(35):37043-53. doi: 10.18632/oncotarget.6158.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias